Sonoma Pharmaceuticals
SNOA
14 hedge funds and large institutions have $242K invested in Sonoma Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.
239% more capital invested
Capital invested by funds: $71.5K → $242K (+$171K)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
17% more funds holding
Funds holding: 12 → 14 (+2)
3.13% more ownership
Funds ownership: 2.04% → 5.17% (+3.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HBCM
Heron Bay Capital Management
Bloomfield Hills,
Michigan
|
+$102K |
| 2 |
Renaissance Technologies
New York
|
+$53.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$38K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.45K |
| 5 |
QWM
Quaker Wealth Management
Moorestown,
New Jersey
|
+$9 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$25K |
| 2 |
Citigroup
New York
|
-$1.78K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.35K |
| 4 |
JP Morgan Chase
New York
|
-$54 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HBCM
1
Heron Bay Capital Management
Bloomfield Hills,
Michigan
| $96.1K | +$102K | +33,782 | New |
|
|
2
Renaissance Technologies
New York
| $50.6K | +$53.8K | +17,800 | New |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $50.6K | +$2.45K | +812 | +5% |
|
|
4
UBS Group
Zurich,
Switzerland
| $41K | +$38K | +12,565 | +678% |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $2.85K | -$1.35K | -447 | -31% |
|
|
6
JP Morgan Chase
New York
| $344 | -$54 | -18 | -13% |
|
7
BlackRock
New York
| $321 | – | – | – |
|
8
US Bancorp
Minneapolis,
Minnesota
| $71 | – | – | – |
|
9
Bank of America
Charlotte,
North Carolina
| $49 | +$6 | +2 | +13% |
|
10
Morgan Stanley
New York
| $11 | – | – | – |
|
|
AF
11
Allworth Financial
Folsom,
California
| $9 | – | – | – |
|
|
QWM
12
Quaker Wealth Management
Moorestown,
New Jersey
| $9 | +$9 | +3 | New |
|
|
DB
13
Danske Bank
Copenhagen K,
Denmark
| $3 | – | – | – |
|
|
HF
14
HRT Financial
New York
| – | -$25K | -11,843 | Closed |
|
|
15
Citigroup
New York
| – | -$1.78K | -811 | Closed |
|
16
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$3 | +1 | New |
|
SNOA Hedge Fund Activity: Q2 2025 in Review
14 of the 7,603 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q2 2025, worth a combined $242K — up 239% from $71.5K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new SNOA positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Heron Bay Capital Management, opening a new position worth an estimated $102K. The largest seller was HRT Financial, exiting entirely with an estimated $25K sold.
- 14 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q2 2025, up from 12 in Q1 2025.
- Funds reported $242K of Sonoma Pharmaceuticals stock for Q2 2025, up 239% quarter-over-quarter.
- 4 funds opened new Sonoma Pharmaceuticals positions in Q2 2025 and 2 closed out, a net change of +2 holders.
- The largest Sonoma Pharmaceuticals buyer in Q2 2025 was Heron Bay Capital Management, an estimated $102K added.
- The largest Sonoma Pharmaceuticals seller in Q2 2025 was HRT Financial, an estimated $25K sold.
Based on aggregated 13F filings for Q2 2025.